CANQURA consists of 3 major compounds (QURA100, QURA200 and QURA300), that have shown positive indications for several other cancer types, including leukaemia, prostate, ovarian, liver, pancreatic, and kidney cancer.   The patented concept is based on ground breaking new QS (Quillaja saponaria Molina) nano-particle developed by Prof Bror Morein and his team.

CANQURA compounds are based on saponin fractions of Quillaja saponaria Molina (QS) which have long been known to have cytotoxic activity against cancer cells in vitro, but were considered too toxic to be useful in the clinic.   Our research team has been able to abolish the toxic effect by converting QS fractions into stable nano-particles through the binding of QS to cholesterol.

Two fractions of QS were selected for particle formation, one with an acyl-chain (ASAP) was used to form killing and growth-inhibiting (KGI) particles, and the other without the acyl-chain (DSAP) was used to formulate blocking and balancing effect (BBE) particles. KGI showed significant growth inhibiting and cancer cell-killing activities in nine of 10 AML cell lines while BBE showed similar effects on one cell line.

The third formula, QURA300 is a mixture of QURA100 and 200 has been used on solid tumours mainly. We believe the formulation of QS into nanoparticles has the potential to become a new class of anticancer agents.   In effect CANQURA normalizes afflicted cells – i.e. re-programs them to complete a normal cell cycle resulting ultimately in programmed cell death (apoptosis). With successful funding, we look to start testing this theory in clinical trials by 2016 for Leukemia (AML) in collaboration with the world-famous Karolinska Institute in Stockholm.  


Canqura is licensed to use QURA100 formula for trials with AML (Acute Myeloid Leukemia). Laboratory results with QURA100 have shown significant effects on AML cancer cells by stopping the uncontrolled cancer cell division, diverting the cancer cell to a natural cycle and normal cell death. This “normalization” of the cancer cells is “a therapy with virtually no side effects”. We have embarked on pre-clinical trials with the Karolinska Institute.


The innovation G3 Technology   G3 Technology is a Swedish innovation which by injection increases the bio availability of molecules and biological and medical effects. G3 is an evolution from the two previous generations (G) under the name of ISCOMs , also developed in Uppsala by Bror Morein . G1 generation has been taken over by CSL in Melbourne, Australia and is a leading adjuvant technology. G1 is now on the way out of the vaccine market. Next development Isconova Uppsala launched and is now bought by an American company and is expected to come out commercially for the vaccine industry within 2 years maybe earlier. G1 and G2 are now commercially available for experimentation on laboratory animals. The unique and patented production technology differs substantially from ISCOMens and the equipment is less than 1/20th than ISOMENs. Iscom has three components and G3 has 2 components. Biological platform, through a component of the nanoparticle is a quillaja molecule (QA) with a potent biological effect that control cell activity and makes G3 highly active in areas as diverse as vaccines and cancer but, according to the same mechanism of action G3 particle steer through these two platforms cell activity to divide, perform cell intended activity when finalized goes against a programmed cell death called apoptosis. This occurs through structures on the cell surface called lectins because they react with sugar molecules that cover the entire G3 particle by QA molecule. An important G3 feature is that the technique developed by MoreinX make inaccessible molecules available to the body by incorporating these in G3 i.e. (build & carry) which then can be effectively delivered for biological / medical effect.

Manufacturing and Production     Manufacturing and production are defined and form the basis for future scaling up G3 is superior to its previous generations in terms of robustness, ease of manufacturing and bio- efficacy and versatility that allows for tailoring vaccines for different infections and species. These properties lead to the active drug dose can be reduced significantly for both cancer drugs and vaccines. Lower dose of medicine generally provides fewer side effects as well as cheaper and faster production. Adjuvants are considered to be the key factor for the development of future vaccine.

Our Experts   Moreinx has the services of top Patent Lawyer and an expert in her field, Heléne Fagerlin, M.Sc. Senior Patent Attorney / European Patent Attorney at Fenix Legal KB. FENIX LEGAL KB is ranked among the top patent practitioners world-wide and recognized with the No 1 “Highly recommended” status. Helene is well acquainted with Moreinx technology since working with the developers through previous versions of our current products, and in securing patents for them. With the assistance of Moreinx technicians, Helene makes a final review for Fenix Legal to secure our patent to specific agencies in each country.